Please ensure Javascript is enabled for purposes of website accessibility

Discovering Yet Another Drug Delay

By Dave Williamson - Apr 15, 2013 at 6:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This company is king when it comes to drug delays.

In this video, Fool health-care analyst David Williamson discusses Discovery Labs (NASDAQ: DSCO), as it struggles with yet another delay to its drug Surfaxin. Shares are down 15% on news that the FDA has requested Surfaxin product specifications and a new analytical chemistry method. It took the company an unbelievable five attempts to finally get this drug approved a year ago. David tells investors when they might expect the delays to end, and what the key things to watch with Discovery Labs will be in the meantime, as the company continues to lose out on sales and burn cash.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.